Nasdaq · CIK 0001503802
KPTI Karyopharm Therapeutics Inc.
Insider trading from SEC Form 4. Last filing 11 d ago. Close $0.61 on Oct 9, 2026, +1% from the 52-week low and -94% from the high.
Karyopharm Therapeutics Inc. (KPTI) has 75 SEC Form 4 filings on file from 13 insiders, the latest filed on Oct 2, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 2 open-market sells worth $488, net -$488.
43 open-market trades have been scored at KPTI. The newest: Kristin Abate (Chief Accounting Officer) sold $450 of stock on Oct 1, 2026, filed Oct 2, 2026, scored 15 (weak). The largest of the 43 shown: Richard A. Paulson (President and CEO) sold $116k on Mar 2, 2026, scored 50 (moderate). 6 insiders sold within 14 days of each other around May 14, 2026.
KPTI closed at $0.61 on Oct 9, 2026, 1% above its 52-week low and 94% below its 52-week high.
Last 90 days
Net insider value
-$488
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$488 by 1 insider
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
KPTIOct 9, 2026 · close 0.61
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Karyopharm Therapeutics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Kristin Abate Chief Accounting Officer sell | $450 378 shares | -2% | 0% from low-92% from high | |
| 15Weak | Kristin Abate Chief Accounting Officer sell | $38 19 shares | -0% | - | |
| 30Weak | Kristin Abate Chief Accounting Officer sell | $504 53 shares | -0% | +136% from low-12% from high | |
| 30Weak | Sohanya Roshan Cheng EVP & Chief Commercial Officer sell | $3,078 324 shares | -0% | +136% from low-12% from high | |
| 30Weak | Michael Mano EVP, CLO&Secretary sell | $2,527 266 shares | -0% | +136% from low-12% from high | |
| 40Moderate | Richard A. Paulson President and CEO sell | $21k 2,203 shares | -1% | +136% from low-12% from high | |
| 30Weak | Reshma Rangwala EVP & Chief Medical Officer sell | $3,876 408 shares | -1% | +136% from low-12% from high | |
| 30Weak | Stuart Poulton EVP, Chief Development Officer sell | $3,829 403 shares | -0% | +136% from low-12% from high | |
| 15Weak | Reshma Rangwala EVP & Chief Medical Officer sell | $4,014 449 shares | -1% | +143% from low-9% from high | |
| 30Weak | Kristin Abate Chief Accounting Officer sell | $5,260 559 shares | -2% | +171% from low-5% from high | |
| 36Weak | Sohanya Roshan Cheng EVP & Chief Commercial Officer sell | $43k 4,604 shares | -4% | +171% from low-5% from high | |
| 50Moderate | Richard A. Paulson President and CEO sell | $116k 12,361 shares | -4% | +171% from low-5% from high | |
| 37Weak | Reshma Rangwala EVP & Chief Medical Officer sell | $48k 5,066 shares | -8% | +171% from low-5% from high | |
| 36Weak | Michael Mano EVP, CLO&Secretary sell | $33k 3,526 shares | -4% | +171% from low-5% from high | |
| 37Weak | Stuart Poulton EVP, Chief Development Officer sell | $48k 5,101 shares | -5% | +171% from low-5% from high | |
| 30Weak | Stuart Poulton EVP, Chief Development Officer sell | $3,262 378 shares | -0% | +166% from low-4% from high | |
| 37Weak | Lori Macomber EVP, CFO & Treasurer sell | $10k 1,626 shares | -2% | +85% from low-35% from high | |
| 23Weak | Kristin Abate Chief Accounting Officer sell | $352 50 shares | -0% | +95% from low-32% from high | |
| 23Weak | Kristin Abate Chief Accounting Officer sell | $1,579 265 shares | -1% | +79% from low-40% from high | |
| 15Weak | Kristin Abate Chief Accounting Officer sell | $2,279 362 shares | -3% | +75% from low-58% from high | |
| 30Weak | Kristin Abate Chief Accounting Officer sell | $148 23 shares | -0% | +77% from low-58% from high | |
| 30Weak | Sohanya Roshan Cheng EVP & Chief Commercial Officer sell | $2,090 325 shares | -1% | +77% from low-58% from high | |
| 30Weak | Reshma Rangwala EVP & Chief Medical Officer sell | $2,623 408 shares | -1% | +77% from low-58% from high | |
| 30Weak | Stuart Poulton EVP, Chief Development Officer sell | $2,578 401 shares | -1% | +77% from low-58% from high | |
| 30Weak | Michael Mano SVP, General Counsel&Secretary sell | $1,505 234 shares | -1% | +77% from low-58% from high | |
| 40Moderate | Richard A. Paulson President and CEO sell | $8,083 1,257 shares | -1% | +77% from low-58% from high | |
| 30Weak | Kristin Abate Chief Accounting Officer sell | $81 12 shares | -0% | +100% from low-52% from high | |
| 23Weak | Stuart Poulton EVP, Chief Development Officer sell | $835 191 shares | -1% | +17% from low-72% from high | |
| 23Weak | Kristin Abate Chief Accounting Officer sell | $952 238 shares | -2% | +10% from low-74% from high | |
| 33Weak | Richard A. Paulson President and CEO sell | $1,680 236 shares | -0% | +77% from low-58% from high | |
| 23Weak | Reshma Rangwala EVP & Chief Medical Officer sell | $2,585 419 shares | -1% | +77% from low-58% from high | |
| 25Weak | Richard A. Paulson President and CEO sell | $916 245 shares | -0% | +9% from low-74% from high | |
| 30Weak | Kristin Abate Chief Accounting Officer sell | $3,592 571 shares | -6% | - | |
| 30Weak | Sohanya Roshan Cheng EVP & Chief Commercial Officer sell | $22k 3,445 shares | -9% | - | |
| 35Weak | Michael Mano SVP, General Counsel&Secretary sell | $18k 2,793 shares | -12% | - | |
| 35Weak | Stuart Poulton EVP, Chief Development Officer sell | $22k 3,548 shares | -11% | - | |
| 35Weak | Reshma Rangwala EVP & Chief Medical Officer sell | $23k 3,587 shares | -11% | - | |
| 53Moderate | Richard A. Paulson President and CEO sell | $74k 11,694 shares | -12% | - | |
| 30Weak | Stuart Poulton EVP, Chief Development Officer sell | $3,726 5,914 shares | -2% | - | |
| 33Weak | Richard A. Paulson President and CEO sell | $2,664 4,099 shares | -0% | - | |
| 25Weak | Richard A. Paulson President and CEO sell | $3,175 4,055 shares | -0% | - | |
| 25Weak | Richard A. Paulson President and CEO sell | $2,932 3,620 shares | -0% | - | |
| 25Weak | Richard A. Paulson President and CEO sell | $3,346 3,675 shares | -0% | - |
Transactions
The newest 50 of 103 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Kristin Abate Chief Accounting Officer | SOpen-market sale Common Stock | -378 | $1.19 | $450 | 23,404 | 11 d ago |
| Sep 1, 2026 | Kristin Abate Chief Accounting Officer | SOpen-market sale Common Stock | -19 | $2.02 | $38 | 23,782 | 41 d ago |
| May 21, 2026 | Zhen Su director | AGrant or award Common Stock | +15,508 | $0.00 | $0 | 15,508 | May 26, 2026 |
| May 21, 2026 | Deepika Pakianathan director | AGrant or award Common Stock | +15,508 | $0.00 | $0 | 15,508 | May 26, 2026 |
| May 21, 2026 | Chen Schor director | AGrant or award Common Stock | +15,508 | $0.00 | $0 | 15,508 | May 26, 2026 |
| May 21, 2026 | Garen G Bohlin director | AGrant or award Common Stock | +15,508 | $0.00 | $0 | 18,517 | May 26, 2026 |
| May 21, 2026 | Christy J. Oliger director | AGrant or award Common Stock | +15,508 | $0.00 | $0 | 15,508 | May 26, 2026 |
| May 21, 2026 | Barry E Greene director | AGrant or award Common Stock | +15,508 | $0.00 | $0 | 16,415 | May 26, 2026 |
| May 13, 2026 | Michael Mano EVP, CLO&Secretary | AGrant or award Common Stock | +700 | $0.00 | $0 | 94,664 | May 15, 2026 |
| May 13, 2026 | Reshma Rangwala EVP & Chief Medical Officer | AGrant or award Common Stock | +947 | $0.00 | $0 | 57,237 | May 15, 2026 |
| May 13, 2026 | Sohanya Roshan Cheng EVP & Chief Commercial Officer | AGrant or award Common Stock | +947 | $0.00 | $0 | 108,264 | May 15, 2026 |
| May 13, 2026 | Stuart Poulton EVP, Chief Development Officer | AGrant or award Common Stock | +896 | $0.00 | $0 | 95,224 | May 15, 2026 |
| May 13, 2026 | Richard A. Paulson President and CEO | AGrant or award Common Stock | +4,920 | $0.00 | $0 | 271,950 | May 15, 2026 |
| May 13, 2026 | Kristin Abate Chief Accounting Officer | AGrant or award Common Stock | +121 | $0.00 | $0 | 23,854 | May 15, 2026 |
| May 14, 2026 | Kristin Abate Chief Accounting Officer | SOpen-market sale Common Stock | -53 | $9.50 | $504 | 23,801 | May 15, 2026 |
| May 14, 2026 | Michael Mano EVP, CLO&Secretary | SOpen-market sale Common Stock | -266 | $9.50 | $2,527 | 94,398 | May 15, 2026 |
| May 14, 2026 | Sohanya Roshan Cheng EVP & Chief Commercial Officer | SOpen-market sale Common Stock | -324 | $9.50 | $3,078 | 107,940 | May 15, 2026 |
| May 14, 2026 | Richard A. Paulson President and CEO | SOpen-market sale Common Stock | -2,203 | $9.50 | $21k | 269,747 | May 15, 2026 |
| May 14, 2026 | Reshma Rangwala EVP & Chief Medical Officer | SOpen-market sale Common Stock | -408 | $9.50 | $3,876 | 56,829 | May 15, 2026 |
| May 14, 2026 | Stuart Poulton EVP, Chief Development Officer | SOpen-market sale Common Stock | -403 | $9.50 | $3,829 | 94,821 | May 15, 2026 |
| Apr 21, 2026 | Reshma Rangwala EVP & Chief Medical Officer | SOpen-market sale Common Stock | -449 | $8.94 | $4,014 | 56,290 | Apr 22, 2026 |
| Mar 2, 2026 | Reshma Rangwala EVP & Chief Medical Officer | SOpen-market sale Common Stock | -5,066 | $9.41 | $48k | 56,739 | Mar 3, 2026 |
| Mar 2, 2026 | Kristin Abate Chief Accounting Officer | SOpen-market sale Common Stock | -559 | $9.41 | $5,260 | 22,063 | Mar 3, 2026 |
| Mar 2, 2026 | Stuart Poulton EVP, Chief Development Officer | SOpen-market sale Common Stock | -5,101 | $9.41 | $48k | 94,328 | Mar 3, 2026 |
| Mar 2, 2026 | Sohanya Roshan Cheng EVP & Chief Commercial Officer | SOpen-market sale Common Stock | -4,604 | $9.41 | $43k | 107,317 | Mar 3, 2026 |
| Mar 2, 2026 | Richard A. Paulson President and CEO | SOpen-market sale Common Stock | -12,361 | $9.41 | $116k | 267,030 | Mar 3, 2026 |
| Mar 2, 2026 | Michael Mano EVP, CLO&Secretary | SOpen-market sale Common Stock | -3,526 | $9.41 | $33k | 93,964 | Mar 3, 2026 |
| Feb 17, 2026 | Stuart Poulton EVP, Chief Development Officer | SOpen-market sale Common Stock | -378 | $8.63 | $3,262 | 99,429 | Feb 19, 2026 |
| Feb 5, 2026 | Richard A. Paulson President and CEO | AGrant or award Common Stock | +81,060 | $0.00 | $0 | 279,391 | Feb 9, 2026 |
| Feb 3, 2026 | Lori Macomber EVP, CFO & Treasurer | SOpen-market sale Common Stock | -1,626 | $6.30 | $10k | 85,105 | Feb 4, 2026 |
| Jan 31, 2026 | Stuart Poulton EVP, Chief Development Officer | AGrant or award Common Stock | +32,415 | $0.00 | $0 | 99,807 | Feb 3, 2026 |
| Jan 31, 2026 | Michael Mano EVP, CLO&Secretary | AGrant or award Common Stock | +32,415 | $0.00 | $0 | 97,490 | Feb 3, 2026 |
| Jan 31, 2026 | Lori Macomber EVP, CFO & Treasurer | AGrant or award Common Stock | +32,415 | $0.00 | $0 | 86,731 | Feb 3, 2026 |
| Jan 31, 2026 | Reshma Rangwala EVP & Chief Medical Officer | AGrant or award Common Stock | +32,415 | $0.00 | $0 | 61,805 | Feb 3, 2026 |
| Jan 31, 2026 | Sohanya Roshan Cheng EVP & Chief Commercial Officer | AGrant or award Common Stock | +32,415 | $0.00 | $0 | 111,921 | Feb 3, 2026 |
| Jan 27, 2026 | Kristin Abate Chief Accounting Officer | AGrant or award Common Stock | +92 | $0.00 | $0 | 22,672 | Jan 29, 2026 |
| Jan 28, 2026 | Kristin Abate Chief Accounting Officer | SOpen-market sale Common Stock | -50 | $7.03 | $352 | 22,622 | Jan 29, 2026 |
| Jan 21, 2026 | Kristin Abate Chief Accounting Officer | SOpen-market sale Common Stock | -265 | $5.96 | $1,579 | 22,580 | Jan 22, 2026 |
| Oct 15, 2025 | Kristin Abate Chief Accounting Officer | AGrant or award Common Stock | +12,799 | $0.00 | $0 | 22,845 | Oct 16, 2025 |
| Oct 15, 2025 | Sohanya Roshan Cheng EVP & Chief Commercial Officer | AGrant or award Common Stock | +43,650 | $0.00 | $0 | 79,506 | Oct 16, 2025 |
| Oct 15, 2025 | Lori Macomber EVP, CFO & Treasurer | AGrant or award Common Stock | +43,650 | $0.00 | $0 | 54,316 | Oct 16, 2025 |
| Oct 15, 2025 | Richard A. Paulson President and CEO | AGrant or award Common Stock | +114,285 | $0.00 | $0 | 198,331 | Oct 16, 2025 |
| Oct 15, 2025 | Michael Mano SVP, General Counsel&Secretary | AGrant or award Common Stock | +43,650 | $0.00 | $0 | 65,075 | Oct 16, 2025 |
| Oct 15, 2025 | Stuart Poulton EVP, Chief Development Officer | AGrant or award Common Stock | +39,682 | $0.00 | $0 | 67,392 | Oct 16, 2025 |
| Oct 1, 2025 | Kristin Abate Chief Accounting Officer | SOpen-market sale Common Stock | -362 | $6.30 | $2,279 | 10,046 | Oct 3, 2025 |
| Sep 12, 2025 | Michael Mano SVP, General Counsel&Secretary | AGrant or award Common Stock | +612 | $0.00 | $0 | 21,659 | Sep 16, 2025 |
| Sep 12, 2025 | Stuart Poulton EVP, Chief Development Officer | AGrant or award Common Stock | +888 | $0.00 | $0 | 28,111 | Sep 16, 2025 |
| Sep 12, 2025 | Reshma Rangwala EVP & Chief Medical Officer | AGrant or award Common Stock | +945 | $0.00 | $0 | 29,798 | Sep 16, 2025 |
| Sep 12, 2025 | Sohanya Roshan Cheng EVP & Chief Commercial Officer | AGrant or award Common Stock | +945 | $0.00 | $0 | 36,181 | Sep 16, 2025 |
| Sep 12, 2025 | Kristin Abate Chief Accounting Officer | AGrant or award Common Stock | +46 | $0.00 | $0 | 10,431 | Sep 16, 2025 |
50 of 103 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Kristin AbateChief Accounting Officer
- Garen G Bohlindirector
- Sohanya Roshan ChengEVP & Chief Commercial Officer
- Barry E Greeneceo, president, officer, director
- Lori MacomberEVP, CFO & Treasurer
- Michael ManoEVP, CLO&Secretary
- Christy J. Oligerdirector
- Deepika Pakianathandirector
- Richard A. PaulsonPresident and CEO
- Stuart PoultonEVP, Chief Development Officer
- Reshma RangwalaEVP & Chief Medical Officer
- Chen Schorceo, president, officer, director
- Zhen Sudirector
Questions about KPTI
Answered from the filings on this page, as of the latest one.
Are insiders buying KPTI?
As of Oct 2, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 2 open-market sells worth $488 by 1 insider at Karyopharm Therapeutics Inc. in the last 90 days, net -$488. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade KPTI on the open market?
Kristin Abate (Chief Accounting Officer) sold $450 of KPTI on Oct 1, 2026 and filed the Form 4 on Oct 2, 2026. InsiderTell scored 15 (weak).
How many insiders file Form 4 at Karyopharm Therapeutics Inc.?
13 people have filed a Form 4 at Karyopharm Therapeutics Inc., among them Kristin Abate (Chief Accounting Officer), Garen G Bohlin (director), Sohanya Roshan Cheng (EVP & Chief Commercial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.